查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1813850

美国小分子药物 CDMO 市场规模、份额和趋势分析报告：按药物类型、产品、应用和细分市场预测，2025-2033 年

U.S. Small Molecule CDMO Market Size, Share & Trends Analysis Report By Drug Type (Generics, Innovators), By Product (APIs, Finished Drug Products), By Application (Oncology, CVD, CNS Conditions), And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

美国小分子药物CDMO市场摘要

预计 2024 年美国小分子药物 CDMO 市值将达到 268.5 亿美元，到 2033 年将达到 473.8 亿美元，2025 年至 2033 年的复合年增长率为 6.68%。

市场成长的动力源自于整个医药价值链对外包需求的不断增长。製药公司，尤其是中小企业和虚拟生物技术公司，越来越依赖CDMO来缩短上市时间、优化研发成本，并获得製剂、製程开发、法规事务等方面的专业知识。

此外，製药业的整合和日益增长的成本压力迫使品牌药和学名药公司精简内部运营，专注于核心竞争力。这为美国CDMO创造了更大的机会，使其不仅能够支持国内客户，还能服务于那些追求高品质并符合严格FDA法规的客户。领先的CDMO在产能扩张、持续生产和绿色化学製程方面的投资也持续成长。

美国小分子CDMO市场主要受小分子在FDA核准和在研产品线中持续主导的驱动。到2023年，美国FDA核准的新分子药物（NME）中超过60%将是小分子，包括Ogsiveo（一种用于治疗纤维瘤的药物）和Zurzuvae（一种用于治疗产后忧郁症的药物）等药物。这种稳定的趋势正在为能够提供全面服务（包括配方、放大和监管批量生产）的CDMO带来巨大且持续的需求。占美国早期研发大部分的中小型生技公司通常缺乏内部製造能力，而是依赖CDMO进行临床前和商业生产。加速高价值治疗药物上市时间的需求，特别是在肿瘤学、罕见疾病和中枢神经系统疾病等领域，进一步加速了向具有从 I 期到 III 期支持能力的灵活的美国CDMO 进行外包。

此外，CDMO 正在进行战略投资，以扩大美国的生产和开发布局，以满足国内创新者和寻求进入美国市场的外国生物製药公司的需求。例如，Cambrex 在其位于北卡罗来纳州海波因特的工厂投资超过 5000 万美元，以扩展其小分子製程开发和原料药製造能力。同样，赛默飞世尔科技也透过收购 Patheon 并随后升级美国网路来扩展其在美国的生产能力。总部位于美国的 CDMO 还具有显着的监管和物流优势，因为在美国境内生产可以降低供应链的复杂性，并有助于遵守 FDA 的现行良好生产规范 (cGMP)。

目录

第一章调查方法与范围

第二章执行摘要

第 3 章美国小分子药物 CDMO 市场：变数、趋势与范围

  • 市场体系展望
  • 美国小分子CDMO市场动态
  • 技术格局
  • 定价模式分析
  • 美国小分子 CDMO 市场：分析工具

第四章：美国小分子药物 CDMO 市场：产品预估与趋势分析

  • 细分仪表板
  • 美国小分子药物CDMO市场：产品差异分析
  • 美国小分子药物 CDMO 市场规模与趋势分析（按产品，2021-2033 年）
  • 活性药物成分（API）
  • 成品药品

第五章美国小分子药物CDMO市场：按药物类型估计和趋势分析

  • 细分仪表板
  • 美国小分子药物CDMO市场：药物类型变化分析
  • 美国小分子药物 CDMO 市场规模及趋势分析（按药物类型，2021-2033 年）
  • 创新者
  • 学名药

第六章：美国小分子药物CDMO市场：应用评估与趋势分析

  • 细分仪表板
  • 美国小分子药物CDMO市场：应用趋势分析
  • 美国小分子药物 CDMO 市场规模与趋势分析（按应用，2021-2033 年）
  • 肿瘤学
  • 心血管疾病
  • 中枢神经系统 (CNS) 疾病
  • 自体免疫/炎症
  • 其他的

第七章美国小分子药物 CDMO 市场：按产品、药物类型和应用进行的区域估计和趋势分析

  • 区域市场仪表板
  • 全球区域市场概况
  • 2021-2033 年市场规模、预测与趋势分析
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争态势

  • 公司分类
  • 美国小分子药物CDMO市占率分析（2024年）
  • 公司简介
    • Lonza, Catalent, Inc.
    • Thermo Fisher Scientific Inc.
    • Cambrex Corporation
    • Bellen Chemistry
    • Siegfried Holding AG
    • Recipharm AB
    • Eurofins Scientific
    • Aurigene Pharmaceutical Services Ltd
    • CordenPharma International
Product Code: GVR-4-68040-702-9

U.S. Small Molecule CDMO Market Summary

The U.S. small molecule CDMO market size was estimated at USD 26.85 billion in 2024 and is projected to reach USD 47.38 billion by 2033, growing at a CAGR of 6.68% from 2025 to 2033. The growth of the market is due to the rising demand for outsourcing across the pharmaceutical value chain. Pharmaceutical companies, especially small to mid-sized firms and virtual biotech's, increasingly rely on CDMOs to reduce time-to-market, optimize R&D expenditure, and access specialized capabilities in formulation, process development, and regulatory compliance.

In addition, consolidation in the pharmaceutical industry and growing cost pressures have pushed both innovator and generic drug companies to streamline internal operations and focus on core competencies. This has expanded opportunities for U.S.-based CDMOs to support not only domestic but also clients seeking quality and compliance with stringent FDA regulations. Increasing investments in capacity expansion, continuous manufacturing, and green chemistry processes by leading CDMOs are also contributing to long-term growth.

The U.S. small molecule CDMO market is mainly driven by the ongoing dominance of small molecule drugs in FDA approvals and active pipelines. In 2023, over 60% of the new molecular entities (NMEs) approved by the U.S. FDA were small molecules, including drugs like Ogsiveo (for desmoid tumors) and Zurzuvae (for postpartum depression). This steady trend creates a significant and recurring demand for CDMOs that can provide comprehensive services such as formulation, scale-up, and regulatory batch manufacturing. Small and mid-sized biotech companies, which make up most of the early-stage R&D in the U.S., often lack in-house manufacturing capabilities and instead depend on CDMOs for both preclinical and commercial production. The need to reduce time-to-market for high-value therapeutics-especially in fields like oncology, rare diseases, and CNS disorders-further speeds up outsourcing to flexible, U.S.-based CDMOs with Phase I-III support capabilities.

Moreover, the strategic investment by CDMO companies to expand their U.S. manufacturing and development footprint, catering to both domestic innovators and foreign biopharma looking for U.S. market access. For instance, Cambrex invested over $50 million in its High Point, North Carolina facility to expand process development and API manufacturing capacity for small molecules. Similarly, Thermo Fisher Scientific has been expanding its U.S. capacity through its acquisition of Patheon and subsequent upgrades across its U.S. network. There's also a strong regulatory and logistics advantage for U.S.-based CDMOs, as manufacturing within the U.S. reduces supply chain complexity and supports compliance with FDA current Good Manufacturing Practices (cGMP).

U.S. Small Molecule CDMO Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. small molecule CDMO market report based on product, drug type, application and region.

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Active Pharmaceutical Ingredients (API)
  • Finished Drug Products
  • Drug Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Innovators
  • Generics
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Oncology
  • Cardiovascular Disease
  • Central Nervous System (CNS) Conditions
  • Autoimmune/Inflammation
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Value chain based analysis (Model 2)
    • 1.7.3. Multivariate Analysis (Model 3)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Small Molecule CDMO Market: Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. U.S. Small Molecule CDMO Market Dynamics
    • 3.2.1. Market Driver Impact Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Technological Landscape
  • 3.4. Pricing Model Analysis
  • 3.5. U.S. Small Molecule CDMO Market: Analysis Tools
    • 3.5.1. Porter's Five Forces Analysis
    • 3.5.2. PESTEL Analysis

Chapter 4. U.S. Small Molecule CDMO Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Small Molecule CDMO Market Product Movement Analysis
  • 4.3. U.S. Small Molecule CDMO Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
  • 4.4. Active Pharmaceutical Ingredients (API)
    • 4.4.1. Active Pharmaceutical Ingredients (API) Market Estimates and Forecasts, 2021 - 2033 (USD million)
  • 4.5. Finished Drug Products
    • 4.5.1. Finished Drug Products Market Estimates and Forecasts, 2021 - 2033 (USD million)

Chapter 5. U.S. Small Molecule CDMO Market: Drug Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Small Molecule CDMO Market Drug Type Movement Analysis
  • 5.3. U.S. Small Molecule CDMO Market Size & Trend Analysis, by Drug Type, 2021 to 2033 (USD Million)
  • 5.4. Innovators
    • 5.4.1. Innovators Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Generics
    • 5.5.1. Generics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Small Molecule CDMO Market: Application Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Small Molecule CDMO Market Application Movement Analysis
  • 6.3. U.S. Small Molecule CDMO Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
  • 6.4. Oncology
    • 6.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Cardiovascular Disease
    • 6.5.1. Cardiovascular Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Central Nervous System (CNS) Conditions
    • 6.6.1. Central Nervous System (CNS) Conditions Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Autoimmune/Inflammation
    • 6.7.1. Autoimmune/Inflammation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Others
    • 6.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Small Molecule CDMO Market: Regional Estimates & Trend Analysis by Product, Drug Type, Application

  • 7.1. Regional Market Dashboard
  • 7.2. Global Regional Market Snapshot
  • 7.3. Market Size, & Forecasts, Trend Analysis, 2021 to 2033
  • 7.4. North America
    • 7.4.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Europe
    • 7.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Competitive Scenario
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Competitive Scenario
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Competitive Scenario
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Competitive Scenario
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. MEA
    • 7.8.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Competitive Scenario
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Competitive Scenario
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Competitive Scenario
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Competitive Scenario
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. U.S. Small Molecule CDMO Market Share Analysis, 2024
  • 8.3. Company Profiles
    • 8.3.1. Lonza, Catalent, Inc.
      • 8.3.1.1. Company overview
      • 8.3.1.2. Financial performance
      • 8.3.1.3. Product benchmarking
      • 8.3.1.4. Strategic initiatives
    • 8.3.2. Thermo Fisher Scientific Inc.
      • 8.3.2.1. Company overview
      • 8.3.2.2. Financial performance
      • 8.3.2.3. Product benchmarking
      • 8.3.2.4. Strategic initiatives
    • 8.3.3. Cambrex Corporation
      • 8.3.3.1. Company overview
      • 8.3.3.2. Financial performance
      • 8.3.3.3. Product benchmarking
      • 8.3.3.4. Strategic initiatives
    • 8.3.4. Bellen Chemistry
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Siegfried Holding AG
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Recipharm AB
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Eurofins Scientific
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Aurigene Pharmaceutical Services Ltd
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. CordenPharma International
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives

List of tables

  • Table 1 List of abbreviations
  • Table 2 U.S. Small Molecule CDMO market, by product, 2021 - 2033 (USD Million)
  • Table 3 U.S. Small Molecule CDMO market, by drug type, 2021 - 2033 (USD Million)
  • Table 4 U.S. Small Molecule CDMO market, by application, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Small Molecule CDMO market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Market formulation & validation
  • Fig. 7 Commodity flow analysis
  • Fig. 8 Value-Chain-Based Sizing & Forecasting
  • Fig. 9 QFD model sizing & forecasting
  • Fig. 10 Bottom-up approach
  • Fig. 11 Market snapshot
  • Fig. 12 Segment snapshot
  • Fig. 13 Segment snapshot
  • Fig. 14 Segment snapshot
  • Fig. 15 Competitive landscape snapshot
  • Fig. 16 Parent market outlook, 2024 (USD Million)
  • Fig. 17 Ancillary market outlook, 2024 (USD Million)
  • Fig. 18 U S Small Molecule CDMO market dynamics
  • Fig. 19 Porter's five forces analysis
  • Fig. 20 PESTEL analysis
  • Fig. 21 U S Small Molecule CDMO market Product outlook: Segment dashboard
  • Fig. 22 U S Small Molecule CDMO market, by Product segment: Market share, 2025 & 2033
  • Fig. 23 Active Pharmaceutical Ingredients (API) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Finished Drug Products market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 U S Small Molecule CDMO market Drug Type outlook: Segment dashboard
  • Fig. 26 U S Small Molecule CDMO market, by Drug Type segment: Market share, 2024 & 2033
  • Fig. 27 Innovators market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Generics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 U S Small Molecule CDMO market Application outlook: Segment dashboard
  • Fig. 30 U S Small Molecule CDMO market, by Application segment: Market share, 2024 & 2033
  • Fig. 31 Oncology market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Cardiovascular Disease market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Central Nervous System (CNS) Conditions market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Autoimmune/Inflammation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Others market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Market participant categorization
  • Fig. 37 Heat map analysis